Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Keytruda | Pembrolizumab | MUC First line | Do not reimburse | Complete | ||
Dovato | dolutegravir / lamivudine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Tegsedi | inotersen | hereditary transthyretin amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Vitrakvi | Larotrectinib | NTRKplus solid tumours | Do not reimburse | Complete | ||
Tecentriq | Atezolizumab | Small Cell Lung Cancer (SCLC) | Do not reimburse | Complete | ||
Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Rydapt | Midostaurin | Systemic Mastocytosis | Do not reimburse | Complete | ||
Vocabria and Cabenuva | cabotegravir sodium cabotegravir-rilpivirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete |